CA2228379A1 - Utilisation combinee d'interleukine-10 et de cyclosporine pour une therapie immunosuppressive - Google Patents

Utilisation combinee d'interleukine-10 et de cyclosporine pour une therapie immunosuppressive Download PDF

Info

Publication number
CA2228379A1
CA2228379A1 CA002228379A CA2228379A CA2228379A1 CA 2228379 A1 CA2228379 A1 CA 2228379A1 CA 002228379 A CA002228379 A CA 002228379A CA 2228379 A CA2228379 A CA 2228379A CA 2228379 A1 CA2228379 A1 CA 2228379A1
Authority
CA
Canada
Prior art keywords
interleukin
cells
csa
cyclosporin
mlr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002228379A
Other languages
English (en)
Inventor
Waleed Tadmori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2228379A1 publication Critical patent/CA2228379A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une combinaison d'interleukine-10 et de cyclosporine pour éviter la réaction de la greffe contre l'hôte, le rejet de la greffe par l'hôte et comme traitement contre les maladies auto-immunes. On a découvert que l'administration d'une combinaison d'interleukine-10 et de cyclosporine a un effet synergique d'inhibition de la prolifération des leucocytes T. L'utilisation simultanée de ces deux agents évite les problèmes de toxicité associés avec des doses plus élevées de cyclosporine.
CA002228379A 1995-08-09 1996-08-06 Utilisation combinee d'interleukine-10 et de cyclosporine pour une therapie immunosuppressive Abandoned CA2228379A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US205795P 1995-08-09 1995-08-09
US60/002,057 1995-08-09
US61995896A 1996-03-20 1996-03-20
US08/619,958 1996-03-20

Publications (1)

Publication Number Publication Date
CA2228379A1 true CA2228379A1 (fr) 1997-02-20

Family

ID=26669861

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002228379A Abandoned CA2228379A1 (fr) 1995-08-09 1996-08-06 Utilisation combinee d'interleukine-10 et de cyclosporine pour une therapie immunosuppressive

Country Status (5)

Country Link
EP (1) EP0845994A1 (fr)
JP (1) JPH11510806A (fr)
AU (1) AU712606B2 (fr)
CA (1) CA2228379A1 (fr)
WO (1) WO1997005896A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1864999A (en) * 1997-12-15 1999-07-05 Universite Laval Methods and compositions for improving the success of cell transplantation in a host
EP1000626A1 (fr) * 1998-09-18 2000-05-17 Applied Research Systems ARS Holding N.V. Antagoniste de récepteur de chemokine et cyclosporine en thérapie combinée
JP3135532B2 (ja) 1998-09-29 2001-02-19 松下電送システム株式会社 ネットワークファクシミリ装置
US6577712B2 (en) 2000-04-07 2003-06-10 Telefonaktiebolaget Lm Ericsson (Publ) Distributed voice mail system
AU2002952492A0 (en) * 2002-11-06 2002-11-21 Cbio Limited Chaperonin 10 immunosuppression
KR20160083884A (ko) 2013-11-01 2016-07-12 스페리움 바이오메드 에스.엘. 치료제 및 미용제의 경피 전달을 위한 봉입체

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2131524A1 (fr) * 1992-03-04 1993-09-16 Maria-Grazia Roncarolo Utilisation de l'interleukine-10 pour eliminer la reaction du greffon contre l'hote
SK281806B6 (sk) * 1992-10-01 2001-08-06 Schering Corporation Použitie il-10 na prípravu liečiva na prevenciu diabetes mellitus
CA2155109A1 (fr) * 1993-02-01 1994-08-18 Daniel Abramowicz Utilisation d'une composition pharmaceutique renfermant une quantite efficace d'interleukine-10, un analogue et (ou) un agoniste d'interleukine-10

Also Published As

Publication number Publication date
JPH11510806A (ja) 1999-09-21
EP0845994A1 (fr) 1998-06-10
AU6842296A (en) 1997-03-05
WO1997005896A1 (fr) 1997-02-20
AU712606B2 (en) 1999-11-11

Similar Documents

Publication Publication Date Title
CA2087525C (fr) Immunotherapie adoptive au moyen de l'interleukine 7
Trinchieri Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes
US9301979B2 (en) Method for attenuating immune response using mesenchymal stem cells and cytokines
RU2280255C2 (ru) Модуляция il-2- и il-15-опосредованных т-клеточных ответов
US6165785A (en) Bone marrow cultures for developing suppressor and stimulator cells for research and therapeutic applications
EP0422186B1 (fr) Utilisation de l'oncostatine m pour la suppression des antigenes mhc
CA2205430C (fr) Procede de fabrication d'un medicament destine au traitement de l'immunodeficience secondaire
WO2003087320A2 (fr) Antagonistes de il-21 et modulation des reponses des lymphocytes t induites par il-21
SK21195A3 (en) Pharmaceutical substance containing il-4 and/or il-10 or antibodies against il-4 and il-10, method of manufacture and use thereof
Zhong et al. Small peptide analogs to stromal derived factor–1 enhance chemotactic migration of human and mouse hematopoietic cells
US6074635A (en) T cell activation
NZ259584A (en) Cancer treatment using interleukin 10 activated peripheral blood mononuclear cells optionally combined with il-10 alone or in combination with il-2 or alpha interferon (alpha-ifn), to stimulate peripheral blood mononuclear cells
CA2228379A1 (fr) Utilisation combinee d'interleukine-10 et de cyclosporine pour une therapie immunosuppressive
Bernengo et al. Immunomodulation and Sézary syndrome: experience with thymopentin (TP‐5)
US6022536A (en) Combined use of interleukin 10 and cyclosporin for immunosuppression therapy
Tokuda et al. The inhibitory effect of human interferon α on the generation of lymphokine-activated killer activity
Vallera et al. Antitumor protection from the murine T-cell leukemia/lymphoma EL4 by the continuous subcutaneous coadministration of recombinant macrophage-colony stimulating factor and interleukin-2
Ulchaker et al. Interferon-γ production by T lymphocytes from renal cell carcinoma patients: evidence of impaired secretion in response to interleukin-12
EP0561927B1 (fr) Compositions pharmaceutiques destinees au traitement des affections malignes a lymphocytes b
AU643245B2 (en) A pharmaceutical preparation for the maturation of prothymocytes
Lotze et al. Interleukin-2 as a pharmacologic reagent
WO2000009150A2 (fr) Cytokines et recepteur de cytokines, agoniste, antagoniste et/ou combinaison d'anticorps a usage therapeutique
MXPA98001091A (en) Combined use of interleukin-10 and cyclosporine for immunosupres therapy
Jadus et al. Effects of interleukin 4 upon human tumoricidal cells obtained from patients bearing solid tumors
Miltenburg et al. Short-term lymphokine stimulation of human peripheral blood mononuclear cells generates cytolytic activity against endothelial cells: involvement of natural killer cells.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead